Human Data, Robot Hands: Where Automation Goes Next
High-quality real-world data has been a major bottleneck for teaching robot hands: A video can show movement without measuring touch or force.
NOVT - Novanta Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$194.00
DETAILS
HIGH:
$194.00
LOW:
$194.00
MEDIAN:
$194.00
CONSENSUS:
$194.00
UPSIDE:
38.63%
Stock News
Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026
Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Rober
Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026, in Chicago, Illinois. About Novanta Novanta is a leading global supplier of core technology solutions that giv.
How to Invest in AI Drug Discovery
.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2026 results after the close of U.S. financial markets on Monday, November 9, 2026. The Company will host a conference call on Tuesday, November 10, 2026 at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conf.
Eltek (NASDAQ:ELTK) vs. Novanta (NASDAQ:NOVT) Financial Survey
Eltek (NASDAQ: ELTK - Get Free Report) and Novanta (NASDAQ: NOVT - Get Free Report) are both technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation. Volatility and Risk Eltek has a beta of 0.68, suggesting
Analyzing Senstar Technologies (NASDAQ:SNT) and Novanta (NASDAQ:NOVT)
Novanta (NASDAQ: NOVT - Get Free Report) and Senstar Technologies (NASDAQ: SNT - Get Free Report) are both technology companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Profitability This table compares Novanta and Senstar Technologies' net
How to Build a Humanoid Body
Last month we broke down the three key areas needed to build your own humanoid. We have already looked at the companies behind the technologies required to build a humanoid's brain.
Are Robots the New Normal? Bet on these ETFs to Invest in the Future
Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector's growth.
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Novanta Inc. $NOVT
Connor Clark and Lunn Investment Management Ltd. acquired a new position in Novanta Inc. (NASDAQ: NOVT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,845 shares of the technology company's stock, valued at approximately $786,000. Several other large investors have
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical a.
Recent Price Trend in Novanta (NOVT) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Novanta (NOVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice
Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Novanta Inc. $NOVT Shares Bought by Bank of America Corp DE
Bank of America Corp DE increased its stake in Novanta Inc. (NASDAQ: NOVT) by 18.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 456,241 shares of the technology company's stock after acquiring an additional 70,728 shares during the
Amundi Purchases 3,516 Shares of Novanta Inc. $NOVT
Amundi increased its position in shares of Novanta Inc. (NASDAQ: NOVT) by 17.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,187 shares of the technology company's stock after buying an additional 3,516 shares during the quarter. Amundi owned 0.07% of
Novanta Q2 Earnings Call Highlights
Novanta (NASDAQ: NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra said reported revenue grew 10% year over year during the quarter, while adjusted EBITDA increased 16%
Novanta Q2 Earnings Call Highlights
Novanta NASDAQ: NOVT reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition.
Novanta Inc. (NOVT) Q2 2026 Earnings Call Transcript
Novanta Inc. (NOVT) Q2 2026 Earnings Call Transcript
Novanta (NOVT) Tops Q2 Earnings and Revenue Estimates
Novanta (NOVT) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.76 per share a year ago.
Novanta Announces Financial Results for the Second Quarter 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2026. Financial Highlights Three Months Ended (In millions, except per share amounts) July 3, June 27, 2026 2025 GAAP Revenue $ 265.8 $ 241.0 Operating Income $ 18.1 $ 14.9 Net Income $ 12.5 $ 4.5 Diluted EPS $ 0.30 $ 0.12.
Price Targets
Novanta price target raised to $194 from $180 at Baird
$194.00
(was $168.29)
Robert W. Baird
Novanta price target raised to $180 from $173 at Baird
$180.00
(was $164.34)
Quinn Fredrickson
·
Robert W. Baird
Novanta price target raised to $150 from $138 at Baird
$150.00
(was $134.67)
Robert Mason
·
Robert W. Baird
Novanta price target lowered to $160 from $169 at Baird
$160.00
(was $143.37)
Robert W. Baird
Novanta price target raised to $175 from $170 at Baird
$175.00
(was $174.36)
Robert Mason
·
Robert W. Baird